MetLife Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

MetLife Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	75,061 +6,389	+9%	+$141K	0.01%	1183
2026 Q1	$1.53M	Sell	68,672 -1,793	-3%	-$42.8K	0.01%	1199
2025 Q4	$1.88M	Sell	70,465 -3,647	-5%	-$87.2K	0.01%	1102
2025 Q3	$1.58M	Buy	+74,112	New	+$1.75M	0.01%	1217
2025 Q2	–	Sell	-71,835	Closed	-$1.19M	–	2732
2025 Q1	$1.19M	Sell	71,835 -1,213	-2%	-$22K	0.01%	1274
2024 Q4	$1.34M	Buy	73,048 +2,669	+4%	+$43.1K	0.01%	1266
2024 Q3	$1.08M	Hold	70,379	–	–	0.01%	1348
2024 Q2	$1.14M	Buy	70,379 +6,624	+10%	+$107K	0.01%	1274
2024 Q1	$1.18M	Hold	63,755	–	–	0.01%	1213
2023 Q4	$2M	Hold	63,755	–	–	0.01%	944
2023 Q3	$1.33M	Hold	63,755	–	–	0.01%	1090
2023 Q2	$1.53M	Hold	63,755	–	–	0.01%	1048
2023 Q1	$1.2M	Sell	63,755 -2,596	-4%	-$49.4K	0.01%	1135
2022 Q4	$1.06M	Hold	66,351	–	–	0.01%	1189
2022 Q3	$1.09M	Hold	66,351	–	–	0.01%	1141
2022 Q2	$935K	Hold	66,351	–	–	0.01%	1242
2022 Q1	$1.61M	Buy	66,351 +23,265	+54%	+$563K	0.01%	1082
2021 Q4	$1.01M	Hold	43,086	–	–	0.01%	1118
2021 Q3	$716K	Hold	43,086	–	–	0.01%	1315
2021 Q2	$1.05M	Buy	+43,086	New	+$973K	0.01%	1136
2020 Q2	–	Sell	-48,173	Closed	-$2.04M	–	2296
2020 Q1	$2.04M	Hold	48,173	–	–	0.03%	601
2019 Q4	$2.06M	Buy	48,173 +2,065	+4%	+$89.8K	0.02%	799
2019 Q3	$1.66M	Sell	46,108 -3,563	-7%	-$108K	0.02%	856
2019 Q2	$1.33M	Sell	49,671 -99,342	-67%	-$2.54M	0.01%	984
2019 Q1	$4M	Buy	149,013 +103,194	+225%	+$2.41M	0.01%	942
2018 Q4	$741K	Hold	45,819	–	–	0.01%	1147
2018 Q3	$951K	Hold	45,819	–	–	0.01%	1151
2018 Q2	$700K	Buy	+45,819	New	+$817K	0.01%	1202

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's ACAD Position: Q2 2026 in Review

MetLife Investment Management increased its Acadia Pharmaceuticals (ACAD) stake by 9.3% in Q2 2026, buying an estimated $141K and bringing the position to 75,061 shares worth $1.9M. The position accounts for 0.01% of the portfolio, ranked #1183.

MetLife Investment Management first reported a position in ACAD in Q2 2018 and has held it in 28 quarters since. The position peaked at $4M in Q1 2019. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

MetLife Investment Management held 75,061 shares of Acadia Pharmaceuticals worth $1.9M as of Q2 2026.
MetLife Investment Management bought 6,389 Acadia Pharmaceuticals shares in Q2 2026, an estimated $141K.
Acadia Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1183 holding.
MetLife Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 28 quarters since.
MetLife Investment Management's Acadia Pharmaceuticals position peaked at $4M in Q1 2019.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.